Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coegin PharmaNGM:COEGIN +1.84%15 Earnings per Share (Diluted) is kr-0.84 as of Jun. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 1,155 Biotechnology companies, Coegin Pharma ranks worse than 99.48% on this metric.
Coegin Pharma's EPS (Basic) for the
three
months ended in Jun. 2026 was kr-0.21.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.84.
Coegin Pharma's EPS without NRI for the
three
months ended in Jun. 2026 was kr-0.21.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.84.
During the past 3 years, the average EPS without NRIGrowth Rate was -146.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -101.60% per year.
During the past 9 years, Coegin Pharma's highest 3-Year average EPS without NRI Growth Rate was 85.20% per year. The lowest was -211.50% per year. And the median was -35.55% per year.
Coegin Pharma (NGM:COEGIN) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Coegin Pharma Earnings per Share (Diluted) Related Terms
Coegin Pharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Coegin Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's PE Ratio falls into.
Coegin Pharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Coegin Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr-0.84 mean?
Coegin Pharma (NGM:COEGIN) has a Earnings per Share (Diluted) of kr-0.84 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Coegin Pharma and its competitors. According to the industry distribution chart, Coegin Pharma ranks #1149 out of 1155 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Coegin Pharma's Earnings per Share (Diluted) too high?
Coegin Pharma's current Earnings per Share (Diluted) is kr-0.84. Based on the distribution chart, Coegin Pharma ranks #1149 out of 1155 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coegin Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #1149 out of 1155 companies for Earnings per Share (Diluted). This places Coegin Pharma in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Coegin Pharma and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coegin Pharma's current Earnings per Share (Diluted) is kr-0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Earnings per Share (Diluted) of kr-0.84. The current Earnings per Share (Diluted) is kr-0.84. Coegin Pharma's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Earnings per Share (Diluted) is kr-0.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
15GF Score
Get the complete analysis for NGM:COEGIN
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
